it depends on the company, recently BOT a similar cannabis company released a trial results. The results were good but the market did not understand the scientific terminology in the announcement so many sold
Howere, they had only two trails going on, IHL needs only one of the 6 programs to progress. There are peer reviewed published research supporting that all 6 programs actually work. All 6 programs showed good results in Vivo. IHL was told that all 6 program will qualify for FDA fast approval.
also BOT was trying for a condition with an existing medication in the market while all 6 programs have no existing approved medicine. That’s the same that GW pharma did which got acquire for 7 times the share price for only one approved drug.
IHL Price at posting:
35.0¢ Sentiment: Hold Disclosure: Held